All-Cause and Pneumococcal Community-Acquired Pneumonia Hospitalizations Among Adults in Tennessee and Georgia.

ABSTRACT:

Importance

Although the use of pneumococcal conjugate vaccines (PCV) has reduced the overall burden of pneumococcal disease, recent measurements of pneumococcal pneumonia incidence are lacking.

Objective

To prospectively quantify the burden of pneumococcal pneumonia and to assess the potential impact of the recently approved adult-specific 21-valent pneumococcal conjugate vaccine (V116).

Design, settings, and participants

This cross-sectional study for prospective active surveillance included adults residing in defined catchment areas in Tennessee and Georgia hospitalized with clinical and radiographical evidence of community-acquired pneumonia (CAP) at 3 hospitals between 2018 and 2022. Data were analyzed from July 2024 to January 2025.

Main outcomes and measures<

SUBMITTER: Grijalva CG 

PROVIDER: S-EPMC12329615 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature